High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2

References

• Akiyama, S., et al., 2021. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Annals of the Rheumatic Diseases, 80 (3), 384–391.
   PubMed Web of Science ®Google Scholar
• Allocca, M., et al., 2020. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clinical Gastroenterology and Hepatology, 18 (9), 2134–2135.
   PubMed Web of Science ®Google Scholar
• An, P., et al., 2020. Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID-19 infection in Wuhan, China.
   Google Scholar
• Aziz, M., et al., 2020. The incidence and outcomes of COVID-19 in IBD patients: a rapid review and meta-analysis. Inflammatory Bowel Diseases, 26 (10), e132–e133.
   PubMed Web of Science ®Google Scholar
• Batlle, D., Wysocki, J., and Satchell, K., 2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clinical Science, 134 (5), 543–545.
   PubMed Web of Science ®Google Scholar
• Bezzio, C., et al., 2020. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut, 69 (7), 1213–1217.
   PubMed Web of Science ®Google Scholar
• Blanco-Melo, D., et al., 2020. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 181 (5), 1036–1045. e9.
   PubMed Web of Science ®Google Scholar
• D’amico, F., et al., 2020. Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. The Lancet. Gastroenterology & Hepatology, 5 (7), 631–632.
   PubMed Web of Science ®Google Scholar
• Danese, S., Cecconi, M., and Spinelli, A., 2020. Management of IBD during the COVID-19 outbreak: resetting clinical priorities. Nature Reviews. Gastroenterology & Hepatology, 17 (5), 253–255.
   PubMed Web of Science ®Google Scholar
• Duret, P.-M., et al., 2020. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. Annals of the Rheumatic Diseases, 79 (9), 1251–1252.
   PubMed Web of Science ®Google Scholar
• Frieman, M., Heise, M., and Baric, R., 2008. SARS coronavirus and innate immunity. Virus Research, 133 (1), 101–112.
   PubMed Web of Science ®Google Scholar
• Garg, M., et al., 2015. Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: a pilot study. Journal of the Renin-Angiotensin-Aldosterone System, 16 (3), 559–569.
   PubMed Web of Science ®Google Scholar
• Garg, M., et al., 2020. Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? Gut, 69 (5), 841–851.
   PubMed Web of Science ®Google Scholar
• Ghavami, S. B., et al., 2018. Variants in two gene members of the T NF ligand superfamily and hepatitis C virus chronic disease. Gastroenterology and Hepatology from Bed to Bench. 11 (Suppl 1), S66–S72. P MID: 30774809; P MCID: P MC6347984.
   Google Scholar
• Ghavami, S.B., et al., 2022. Serological response to SARS-CoV-2 is attenuated in patients with inflammatory bowel disease and can affect immunization. JGH Open, 6 (4), 266–269.
   PubMed Web of Science ®Google Scholar
• Ghavami, S.B., et al., 2020. IBD patients could be silent carriers for novel coronavirus and less prone to its severe adverse events: true or false? Cell Journal, 22, 151.
   PubMed Web of Science ®Google Scholar
• Guan, W.-J., et al., 2020. Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine, 382 (18), 1708–1720.
   PubMed Web of Science ®Google Scholar
• Gubatan, J., et al., 2020. SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in Northern California. Gastroenterology, 159 (3), 1141–1144. e2.
   PubMed Web of Science ®Google Scholar
• Guerra, I., et al., 2021. Incidence, clinical characteristics, and evolution of SARS-CoV-2 infection in patients with inflammatory bowel disease: a single-center study in Madrid, Spain. Inflammatory Bowel Diseases, 27 (1), 25–33.
   PubMed Web of Science ®Google Scholar
• Khalagi, K., et al., 2021. Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 serological surveillance program. Clinical Microbiology and Infection, 27 (11), 1666–1671.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy, S., Lockey, R.F., and Kolliputi, N., 2021. Soluble ACE2 as a potential therapy for COVID-19. American Journal of Physiology. Cell Physiology, 320 (3), C279–C281.
   PubMed Web of Science ®Google Scholar
• Kumar, A., et al., 2021. SARS-CoV-2-specific virulence factors in COVID-19. Journal of Medical Virology, 93 (3), 1343–1350.
   PubMed Web of Science ®Google Scholar
• Li, Y., et al., 2020. Asymptomatic and symptomatic patients with non-severe coronavirus disease (COVID-19) have similar clinical features and virological courses: a retrospective single center study. Frontiers in Microbiology, 11, 1570.
   PubMed Web of Science ®Google Scholar
• Mao, R., et al., 2020. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 5 (7), 667–678.
   PubMed Web of Science ®Google Scholar
• Meffre, E., and Iwasaki, A., 2020. Interferon deficiency can lead to severe COVID. Nature Publishing Nature, 587 (7834), 374–376.
   PubMed Web of Science ®Google Scholar
• Nikpouraghdam, M., et al., 2020. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: a single center study. Journal of Clinical Virology, 127, 104378.
   PubMed Web of Science ®Google Scholar
• Norsa, L., et al., 2020. Uneventful course in patients with inflammatory bowel disease during the severe acute respiratory syndrome Coronavirus 2 outbreak in Northern Italy. Gastroenterology, 159 (1), 371–372.
   PubMed Web of Science ®Google Scholar
• Onder, G., Rezza, G., and Brusaferro, S., 2020. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA, 323 (18), 1775–1776.
   PubMed Web of Science ®Google Scholar
• Poustchi, H., et al., 2021. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. The Lancet. Infectious Diseases, 21 (4), 473–481.
   PubMedGoogle Scholar
• Rodríguez, Y., et al., 2020. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. Journal of Autoimmunity, 114, 102506.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Lago, I., et al., 2020. Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain). Gastroenterology, 159 (2), 781–783.
   PubMed Web of Science ®Google Scholar
• Rojas, A., et al., 2021. Receptor for advanced glycation end-products axis and coronavirus disease 2019 in inflammatory bowel diseases: a dangerous liaison? World Journal of Gastroenterology, 27 (19), 2270–2280.
   PubMed Web of Science ®Google Scholar
• Ruan, Q., et al., 2020. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine, 46 (5), 846–848.
   PubMed Web of Science ®Google Scholar
• Signorelli, C., Scognamiglio, T., and Odone, A., 2020. COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population. Acta Bio Medica: Atenei Parmensis, 91, 175.
   PubMedGoogle Scholar
• Singh, A.K., et al., 2020. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes & Metabolic Syndrome, 14 (4), 303–310.
   PubMed Web of Science ®Google Scholar
• Wang, Y., et al., 2020. Clinical course and outcomes of 344 intensive care patients with COVID-19. American Journal of Respiratory and Critical Care Medicine, 201 (11), 1430–1434.
   PubMed Web of Science ®Google Scholar
• Yadav, V., et al., 2016. Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets. Translational Research, 176, 38–68.
   PubMed Web of Science ®Google Scholar
• Zhang, Q., et al., 2020. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 370 (6515), eabd4570.
   PubMed Web of Science ®Google Scholar
• Zhao, Q., et al., 2020. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. Journal of Medical Virology, 92 (10), 1915–1921.
   PubMed Web of Science ®Google Scholar